drugset / Trial / NCT02518373

Effect of G17DT in Patients With Stage II/III Colorectal Cancer

NCT02518373

Phase 2 Completed 22 enrolled Cancer Advances Inc.
NaSingle-groupOpen-labelTreatment

Summary

This Phase 2 study was an open label, single-center 18-week study to compare basal and meal stimulated plasma gastrin levels before and after treatment with 3 intramuscular injections of 250 µg G17DT, with and without the concomitant administration of Omeprazole.

Timeline

Start
2000-04
Primary completion
2001-02
Completion
2001-02

Drugs

EvaluationDrugModalityDoseRoute
Subject G17DT Immunogen Vaccine 250 ug Intramuscular
Subject Omeprazole Other / unclassified

Indications